CRC Research Update — November 17, 2026
Today's colorectal cancer research highlights
Curated CRC research, accessible, accurate, actionable
The CRC Digest
Tuesday, November 17, 2026
IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.
CRC Research Update
-
RESEARCH
Gut bacteria toxin colibactin linked to early-onset CRC, especially in JapanWhole-genome sequencing reveals that colibactin, a genotoxin from E. coli, leaves mutational signatures in approximately 50% of early-onset CRC cases in Japan, the highest prevalence worldwide. (Cancer Sci)
-
SCREENING
New risk score predicts precancerous polyps in Lynch syndrome patientsA prospective study of 143 Lynch syndrome patients developed the LASS score, which stratifies polyp risk from 14.7% to 57.8% based on age, prior adenomas, and family history; no postcolonoscopy cancers occurred in the cohort. (Hered Cancer Clin Pract)
-
TREATMENT
Daraxonrasib receives first FDA approval for pancreatic cancerThe oral RAS(ON) inhibitor daraxonrasib was approved in the U.S. on August 26, 2026, for metastatic pancreatic ductal adenocarcinoma after at least one prior systemic therapy; the drug is being developed for solid tumors including CRC and lung cancer. (Drugs)
-
REGULATORY
Nomogram developed to predict deep invasion in early colorectal lesionsA retrospective study of 339 patients identified tumor size >20 mm, infiltrative JNET pattern, and infiltrative pit pattern as independent predictors of deep submucosal invasion, aiding decisions on endoscopic versus surgical treatment. (BMC Gastroenterol)
Today's research spans early-life carcinogen exposures, risk stratification tools for hereditary syndromes, and new treatment approvals for RAS-driven tumors.
Get CRC research intelligence delivered weekly, free.
SubscribeCRC Digest
Not Medical Advice
The CRC Digest provides research summaries for informational and educational purposes only. This is not medical advice. Always consult your healthcare provider before making any decisions about your care.
Content is curated with AI assistance and reviewed by the editorial team.
Browse Past Issues · Read our full disclaimer · Manage subscription
Useful? Forward it to a colleague. Many of the topics named here have a live research dossier, trajectory and evidence, at Signal Bureau.
Got this from a colleague? Subscribe here. Readers are added at their own request, by sign-up or through Evolution Labs.
Evolution Accelerator, Inc. (dba Evolution Labs) · 3941 Park Dr., Suite 20341, El Dorado Hills, CA 95762
You are receiving this because you subscribed to CRC Digest (self-serve signup)
Unsubscribe: honored promptly, no login required. · Privacy policy · Manage or delete your data